Eris Lifesciences Q3 PAT grows 11.7% YoY to Rs 100 cr

28 Jan 2022 , 02:37 PM

Consolidated profit before tax stood at Rs 108.9 crore in Q3 FY22, rising 9.75% from Rs 99.2 posted in the same quarter last year. EBITDA grew by 13.5% year on year to Rs 121.7 crore in Q3 FY22. Meanwhile, the drug companys EBITDA margin improved to 36.6% in Q3 FY22 from 34.5% in Q3 FY21.

The company said it grew at 7.8% in Q3 FY22 as compared to IPM growth of 5.7%, outperforming IPM in cardio-metabolic, CNS & womens health therapies.

Shares of Eris Lifesciences were trading 0.36% lower at Rs 706.30 on BSE. The result was announced during market hours today, 28 January 2022.

Eris Lifesciences is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian pharmaceutical market.

Powered by Capital Market – Live News